In AADC deficiency, dopamine agonist therapy provided the patients with few benefits, but, after AADC gene transfer, the patients showed marked improvement in their dystonia symptoms (43). This evidence concerns the gene DDC and aromatic L-amino acid decarboxylase deficiency.